Literature DB >> 23292493

Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV‑3 human ovarian carcinoma cells.

Yan-Ming Lu1, Meng-Li Rong, Chao Shang, Ning Wang, Xiang Li, Yan-Yan Zhao, Shu-Lan Zhang.   

Abstract

The aberrant expression of human epidermal growth factor receptor-2 (HER-2) has been detected in ovarian cancer. However, the role of HER-2 in the development of ovarian cancer has not been sufficiently elucidated. The objective of this study was to determine the role of HER-2 in the apoptosis and metastasis of SKOV-3 ovarian cancer cells. SKOV-3 cells were transfected with three double‑stranded small interfering RNA (siRNA) molecules that target HER-2. Various sequences were synthesized by T7 transcription in vitro to select the most effective HER-2‑silencing siRNA. SKOV-3 cells were examined for growth inhibition using the MTT proliferation assay and apoptosis was assessed using flow cytometry and TUNEL assay. The Matrigel basement memebrane matrix was used to assess invasion and chemotactic mobility, as a model of tumor cell metastasis. Western blot analysis was used to detect the expression of matrix metallopeptidase-9 (MMP-9), E-cadherin, N-cadherin and vimentin. siRNA interference in HER-2 resulted in decreased cell proliferation and invasion and increased apoptosis. Western blot analysis demonstrated a marked increase in E-cadherin and MMP-9 and a reduction in N-cadherin and vimentin protein levels in the SKOV-3 cells. The suppression of HER-2 expression resulted in apoptosis and the inhibition of metastasis of SKOV-3 cells. Therefore, the overexpression of the HER-2 gene can enhance the metastatic potential of SKOV-3 cells by increasing the protein levels of MMP-9. Epithelial-mesenchymal transition may be involved in the HER-2 siRNA-induced invasion and migration of SKOV-3 cells. Taken together, these results suggest that HER-2 functions as an oncogene and may thus be an attractive therapeutic target in SKOV-3 ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23292493     DOI: 10.3892/or.2012.2214

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Expression and clinical significance of lncRNA BC041954 in ovarian cancer.

Authors:  Yan-Ming Lu; Ya-Ru Guo; Meng-Ya Zhou; Yue Wang
Journal:  Exp Ther Med       Date:  2022-04-26       Impact factor: 2.751

2.  Pharmacological Effects of Natural Components Against Ovarian Cancer and Mechanisms.

Authors:  Huidi Liu; Shu-Lin Liu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.

Authors:  Spencer I Kozinn; Niall J Harty; Jessica M Delong; Christina Deliyiannis; Tanya Logvinenko; Ian C Summerhayes; John A Libertino; Antonia H Holway; Kimberly M Rieger-Christ
Journal:  Genes Cancer       Date:  2013-01

4.  Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9.

Authors:  Huidi Liu; Zheng Zeng; Siwen Wang; Ting Li; Emilio Mastriani; Qing-Hai Li; Hong-Xia Bao; Yu-Jie Zhou; Xiaoyu Wang; Yongfang Liu; Wei Liu; Sijing Hu; Shan Gao; Miao Yu; Yingying Qi; Zhihang Shen; Hongyue Wang; Tingting Gao; Lingqin Dong; Randal N Johnston; Shu-Lin Liu
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

5.  Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma.

Authors:  Xiaoping Song; Kailv Sun; Jianming Hu; Jianghu Zhou
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.